Neurocrine Biosciences vs Sarepta Therapeutics
Neurocrine Biosciences reported revenue of $2.9 billion in fiscal 2025, 1.3 times Sarepta Therapeutics' $2.2 billion in fiscal 2025. Neurocrine Biosciences' revenue grew 21.4% in its latest year, and Sarepta Therapeutics' grew 15.6%. Neurocrine Biosciences had an operating margin of 21.6%, against -31.8% at Sarepta Therapeutics. Free cash flow was $749 million at Neurocrine Biosciences and −$307 million at Sarepta Therapeutics.
Side by side
| Neurocrine Biosciences | Sarepta Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $2.9B | $2.2B |
| Revenue growth | 21.4% | 15.6% |
| Revenue growth a year, last 5 years | 22.3% | 32.4% |
| Gross margin | 98.2% | 98.8% |
| Operating margin | 21.6% | −31.8% |
| Net margin | 16.7% | −32.5% |
| Free cash flow | $749M | −$307M |
| Free cash flow margin | 26.2% | −14.0% |
| Return on capital | 25.6% | −47.2% |
| Net debt to EBITDA | −2.3x | — |
| Dividends and buybacks | $168M | $25M |
| Change in diluted share count | −1.2% | −7.2% |
| Last close | $164.63 | $17.82 |
| P/E at the last close | 24.4× | — |
| Insider trades, last 12 months | sold $77.4 million | sold $417,410 |
| Piotroski F-score | 6 of 9 | 3 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Neurocrine BiosciencesSarepta Therapeutics
Operating margin
Percent of revenue
Neurocrine BiosciencesSarepta Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Neurocrine BiosciencesSarepta Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Neurocrine Biosciences and Sarepta Therapeutics pages.